Join the Mounjaro group to help and get support from people like you.
Mounjaro News (Page 4)
GLP-1 Weight-Loss Meds Could Interfere With Endoscopy, Colonoscopy
TUESDAY, Oct. 1, 2024 – Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy. Now, research finds this scenario is...
Ozempic, Mounjaro Help People With Type 1 Diabetes Control Blood Sugar, Lose Weight
FRIDAY, Sept. 13, 2024 – Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and control their blood sugar levels, a new study...
Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study Finds
TUESDAY, Aug. 20, 2024 – Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes...
Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study Finds
TUESDAY, Aug. 20, 2024 – Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes...
Risks for Mortality, Adverse Heart, Kidney Events Lower With Tirzepatide for T2DM
MONDAY, Aug. 12, 2024 – For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated...
GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D
THURSDAY, July 11, 2024 – For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers...
Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
MONDAY, July 8, 2024 – Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA...
Mounjaro Beats Ozempic for Weight Loss
MONDAY, July 8, 2024 – Mounjaro outperforms Ozempic in helping people lose weight, a new study shows. People taking tirzepatide (Mounjaro, Zepbound) dropped significantly more pounds than those...
ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
WEDNESDAY, June 26, 2024 – Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and obesity, according to a study published online...
GLP-1 Medicine Mounjaro May Be First Drug to Ease Sleep Apnea
FRIDAY, June 21, 2024 – A medication used to manage type 2 diabetes has been found effective in treating sleep apnea. The worldwide clinical trial demonstrates that tirzepatide significantly lowers...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for...
Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight
TUESDAY, May 14, 2024 – Among slow responders to tirzepatide treatment at week 12, 90 percent went on to achieve clinically meaningful weight reduction (≥5 percent) by week 72, according to a study p...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Approves Mounjaro (tirzepatide) Injection for the Treatment of Adults with Type 2 Diabetes
INDIANAPOLIS, May 13, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Diabetes, Type 2